



Global HPV Vaccination: Opportunities and Challenges

April 23-24, 2013 ■ Miami, FL ■ Hilton Miami Downtown

Workshop Overview

Cervical cancer is the second-most common cancer among women worldwide, and more than 80 percent of these cases occur among women in developing countries. HPV vaccines are effective in protecting against infection with HPV types associated with more than 70% of cervical cancer cases, along with other HPV-related cancers and genital warts. A worldwide effort to implement HPV vaccination has potential to dramatically reduce rates of HPV infection and associated conditions. The World Health Organization recommends that HPV vaccines be introduced into national immunization programs where prevention of cervical cancer is a public health priority and vaccine introduction is feasible and sustainable. In this workshop, participants will examine a range of topics relevant to the development of a coordinated global strategy to increase HPV vaccine uptake. Data about effective global vaccination programs may inform some U.S. efforts. The following are some of the issues workshop participants will address.

- **Overview of global epidemiology of HPV infection and related conditions**, including differences among countries at varying income levels and regions; projection of trends for cervical and non-cervical HPV-related disease over the coming decades; global capacity for surveillance of HPV infection and related conditions
- **Overview of global HPV vaccination coverage**, including differences among countries at varying income levels and regions; modeling methods to estimate coverage
- **HPV vaccine policy and financing**, including overview of national vaccine program development and financing mechanisms; leveraging established immunization networks to administer vaccines; establishing sustainable financing for national immunization programs; using cost-effectiveness modeling to support decision making
- **HPV vaccination program development and implementation**, including examination of countries that are developing and implementing HPV vaccination initiatives at the national level; opportunities for HPV vaccine delivery (e.g., school-based programs, development of comprehensive adolescent health platform); challenges associated with development and implementation
- **HPV vaccination program monitoring and evaluation**, including examination of countries that are engaging in HPV vaccination program monitoring and evaluation; resources available for countries to monitor and evaluate program activities

Workshop Chairs

- **Rima F. Khabbaz, MD**, Deputy Director for Infectious Diseases, Centers for Disease Control and Prevention
- **Olufunmilayo Olopade, MD, FACP**, Director, Cancer Risk Clinic, Professor of Medicine and Human Genetics, University of Chicago Medical Center
- **Ted Trimble, MD, MPH**, Director, Center for Global Health, National Cancer Institute